Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Abstract Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, w...

Full description

Bibliographic Details
Main Authors: Xubo Gong, Yi Zhang, Xin He, Milad Moloudizargari, Teng Yu, Lin Wang, Weiwei Liu, Lan Jin, Huiying Xu, Yang Xu, Zhihua Tao, Wenbin Qian
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Experimental Hematology & Oncology
Subjects:
Venetoclax
Acute myeloid leukemia
Hypomethylating agents
Online Access:https://doi.org/10.1186/s40164-023-00424-z

Similar Items

Similar Items